COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,187 Articles (22,713 medRxiv, 8,474 bioRxiv)

Most recent first Previous |  Page 556: Articles 5551-5560  | Next

Highly potent antisense oligonucleotides (ASOs) targeting the SARS-CoV-2 RNA genome
Dauksaite, V., Tas, A., Wachowius, F., Spruit, A., van Hemert, M., Snijder, E., van der Veer, E. P., van Zonneveld, A. J.
10.1101/2022.11.28.518195 — Posted: 2022-11-28
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., Valdez, R., Lauring, A. S., Sheng, Z., Wang, H. H., Gordon, A., Liu, L., Ho, D. D.
10.1101/2022.11.23.517532 — Posted: 2022-11-28
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ1.1 and XBB.
Sullivan, D. J., Franchini, M., Senefeld, J., Joyner, M., Casadevall, A., Focosi, D.
10.1101/2022.11.25.517977 — Posted: 2022-11-28
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
Kim, Y., Jackobsen, H., Fuerholzner, B., Eschke, K., Hoffmann, M., Chaudhry, M. Z., Bertoglio, F., Hust, M., Widera, M., Ciesek, S., Poehlmann, S., Cicin-Sain, L.
10.1101/2022.11.25.517953 — Posted: 2022-11-28
Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2
Bianchini, F., Crivelli, V., Abernathy, M. E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Pedotti, M., De, R., Simonelli, L., Matkovic, M., Toscano, C., Biggiogero, M., Calvaruso, V., Svoboda, P., Cervantes Rincon, T., Fava, T., Podesvova, L., Shanbhag, A. A., Celoria, A., Sgrignani, J., Stefanik, M., Hoenig, V., Pranclova, V., Michalcikova, T., Prochazka, J., Guerrini, G., Mehn, D., Ciabattini, A., Abolhassani, H., Jarrossay, D., Uguccioni, M., Medaglini, D., Pan-Hammarstroem, Q., Calzolai, L., Fernandez, D., Baldanti, F., Franzetti-Pellanda, A., Garzoni, C., Sedlacek, R., Ruzek, D., Varani, L., Cavalli, A., Barnes, C. O., Robbiani, D. F.
10.1101/2022.11.24.515932 — Posted: 2022-11-28
Strengthening response coordination through public health emergency operations centers in Africa: Lessons learned from 56-week webinar sessions, 2020-2021
Eteng, W., Gebrewahid, A. L., Tekeste, S., Mankoula, W., Collard, E., Waya, C., Rosenfeld, E., Wilton, C. M., Muita, M., McGinley, L., Kawe, Y., Abdullah, A., Halm, A., Li, J., Lokossou, V. L., Kanoute, Y., Sonko, I., Aragaw, M.
10.1101/2022.11.22.22282627 — Posted: 2022-11-28
The impacts of social restrictions during the COVID-19 pandemic on the physical activity levels of over 50-year olds: the CHARIOT COVID-19 Rapid Response (CCRR) cohort study
Green, C., Beaney, T., Salman, D., Robb, C., de Jager Loots, C., Giannakopoulou, P., Udeh-Momoh, C. T., Ahmadi Abhari, S., Majeed, A., Middleton, L., McGregor, A.
10.1101/2022.11.23.22282280 — Posted: 2022-11-28
Monoclonal antibody levels and protection from COVID-19
Stadler, E., Burgess, M. T., Schlub, T. E., Chai, K. L., McQuilten, Z. K., Wood, E. M., Polizzotto, M. N., Kent, S. J., Cromer, D., Davenport, M. P., Khoury, D. S.
10.1101/2022.11.22.22282199 — Posted: 2022-11-28
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Assawakosri, S., Kanokudom, S., Suntronwong, N., Chansaenroj, J., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Duangchinda, T., Chantima, W., Pakchotanon, P., Srimuan, D., Thatsanatorn, T., Klinfueng, S., Sudhinaraset, N., Wanlapakorn, N., Mongkolsapaya, J., Honsawek, S., Poovorawan, Y.
10.1101/2022.11.24.22282735 — Posted: 2022-11-27
Heterogeneity of treatment effect of higher dose dexamethasone by geographic region in patients with COVID-19 and severe hypoxemia - A post hoc evaluation of the COVID STEROID 2 trial
Tirupakuzhi Vijayaraghavan, B. K., Granholm, A., Myatra, S. N., Jha, V., Hammond, N., Micallef, S., Munch, M. W., Kjaer, M.-B. N., Moller, M. H., Lange, T., Perner, A., Venkatesh, B.
10.1101/2022.11.23.22282463 — Posted: 2022-11-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).